The pharma-biotech complex and interconnected regional innovation arenas

Urban Studies

Volumn 47, Issue 13, 2010, Pages 2867-2894

  Zeller, Christian ^a  

^a UNIVERSITY OF SALZBURG   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BIOTECHNOLOGY; ECONOMIC DEVELOPMENT; FINANCIAL SYSTEM; HIERARCHICAL SYSTEM; PHARMACEUTICAL INDUSTRY; RESEARCH WORK; STRATEGIC APPROACH; URBAN AREA; URBAN DEVELOPMENT; URBAN ECONOMY;

BASEL; BASEL-STADT; BOSTON; MASSACHUSETTS; NEW JERSEY; SWITZERLAND; UNITED STATES;

EID: 78549266535     PISSN: 00420980     EISSN: 1360063X     Source Type: Journal    
DOI: 10.1177/0042098010377370     Document Type: Article

References (130)

1. Actelion (2009) Actelion: the company. Actelion AG, Allschwil, Switzerland, August.
2. Aoki, N. (2002) Novartis launches recruiting drive gain for Mass. seen, but small firms cite strain on talent pool, The Boston Globe, 13 November, p. D1.
3. Aoki, N. (2003) Many joining Biotech move to Cambridge, The Boston Globe, 19 February, p. A1.
4. Arora, A. and Merges, R.P. (2004) Specialized supply firms, property rights and firm boundaries, Industrial and Corporate Change, 13(3), pp. 451-475.
5. Arpida (2009) Annual report 2008. Arpida AG, Reinach, Switzerland.
6. Arvanitis, S. and Schips, B. (1996) Lage und Perspektive der Gentechnologie in der Schweiz: eine ökonomische Analyse anhand von Firmendaten. Konjunkturforschungsstelle Eidgenössische Technische Hochschule Zürich, Zürich, August.
7. Bagchi-Sen, S., Smith, H.L. and Hall, L. (2004) The US biotechnology industry: industry dynamics and policy, Environment & Planning C, 22(2), pp. 199-216.
8. Birch, K. (2008) Alliance-driven governance: applying a global commodity chains approach to the U.K. biotechnology industry, Economic Geography, 84(1), pp. 83-102.
9. Brown, E., Derudder, C., Parnreiter, C.et al.(2007) World city networks and global commodity chains: towards a world-systems' integration. GaWC Research Bulletin No. 236, Globalization and World Cities Research Network, Loughborough University.
10. Bunnell, T.G. and Coe, N.M. (2001) Spaces and scales of innovation, Progress in Human Geography, 25(4), pp. 569-589.
11. Caves, R.E. (1996) Multinational Enterprise and Economic Analysis, 2nd edn. Cambridge: Cambridge University Press.
12. Chandler, A.D. (1990) Scale and Scope: The Dynamics of Industrial Capitalism. Cambridge, MA: Belknap Press.
13. Chandler, A.D. (2005) Shaping the Industrial Century: The Remarkable Story of the Evolution of the Modern Chemical and Pharmaceutical Industries. Cambridge, MA: Harvard University Press.
14. Chesnais, F. (1997) La mondialisation du capital, new edn. Paris: Syros.
15. Chesnais, F. (2004) Le capital de placement: accumulation, internationalisation, effets économiques et politiques, in: F. Chesnais (Ed.) La finance mondialisé, pp. 15-50. Paris: Éditions La Découverte.
16. Christopherson, S. and Clark, J. (2007) Power in firm networks: what it means for regional innovation systems, Regional Studies, 41(9), pp. 1223-1236.
17. Cooke, P. (2004) The molecular biology revolution and the rise of bioscience megacentres in North America and Europe, Environment and Planning C, 22(2), pp. 161-177.
18. Cooke, P. (2005) Regionally asymmetric knowledge capabilities and open innovation. Exploring 'globalisation 2': a new model of industry organisation, Research Policy, 34(8), pp. 1128-1149.
19. Coriat, B. and Orsi, F. (2002) Establishing a new intellectual property rights regime in the United States: origins, content and problems, Research Policy, 31(8/9), pp. 1491-1507.
20. Cortright, J. and Mayer, H. (2002) Signs of life: the growth of biotechnology in the U.S. The Brookings Institution, Washington, DC.
21. Daniel, S., Richter, M. and Siegenführ, T. (2006) 10 years BioValley: survey and prospects. Technologiestiftung BioMed Freiburg, Freiburg.
22. Delapierre, M. (2000) Vers l'emergence de nouvelle formes d'oligopoles fondes sur la connaissance, in: M. Delapierre, P. Moati and E. M. Mouhoud (Eds) Connaissance et Mondialisation, pp. 97-107. Paris: Economica.
23. Dicken, P., Forsgren, M. and Malmberg, A. (1994) The local embeddedness of transnational corporations, in: A. Amin and N. Thrift (Eds) Globalization, Institutions, and Regional Development in Europe, pp. 23-45. Oxford: Oxford University Press.
24. Donnelly, J.M. (2009) Big drug companies hiring steadily, Boston Business Journal, 22 May.
25. Drews, J. (1998) Die verspielte Zukunft: Wohin geht die Arzneimittelforschung? Basel: Birkhäuser.
26. Drews, J. and Ryser, S. (1996) Innovation deficit in the pharmaceutical industry, Drug Information Journal, 30, pp. 97-108.
27. Drews, J. and Ryser, S. (1997) Pharmaceutical innovation between scientific opportunities and economic constraints, Drug Discovery Today, 2(9), pp. 365-372.
28. Enright, M. (1995) The Swiss pharmaceutical industry, in: M. Enright and R. Weder (Eds) Studies in Swiss Competitive Advantage, pp. 61-111. Bern: Lang.
29. Feldman, M. and Schreuder, Y. (1996) Initial advantage: the origins of the geographic concentration of the pharmaceutical industry in the mid-Atlantic region, Industrial and Corporate Change, 5(4), pp. 839-862.
30. FMI (Friedrich Miescher Institut) (2008) FMI facts 2008. Friedrich Miescher Institut for Biomedical Research (http://www.fmi.ch/downloads/news/media/FMI_facts_english_2008.pdf; accessed 12 August 2009).
31. Friedmann, J. (1995) Where we stand: a decade of world city research, in: P. L. Knox and P. Taylor (Eds) World Cities in a World System, pp. 21-47. Cambridge: Cambridge University Press.
32. Fritz, H. (1992) Industrielle Arzneimittelherstellung: Die pharmazeutische Industrie am Beispiel der Sandoz AG. Stuttgart Wissenschaftliche Verlagsgesellschaft Stuttgart.
33. Gambardella, A. (1995) Science and Innovation: The US Pharmaceutical Industry during the 1980s. Cambridge: Cambridge University Press.
34. Gassmann, O. and Zedwitz, M. von (1999) New concepts and trends in international R&D organization, Research Policy, 28(2/3), pp. 231-250.
35. Gereffi, G., Humphrey, J. and Sturgeon, T. (2005) The governance of global value chains, Review of International Political Economy, 12(1), pp. 78-104.
36. Glaeser, E.L. (2005) Reinventing Boston: 1630-2003, Journal of Economic Geography, 5(1), pp. 119-153.
37. Gray, M. and Parker, E. (1998) Industrial change and regional development: the case of the US biotechnology and pharmaceutical industries, Environment and Planning A, 30(10), pp. 1757-1774.
38. Griffith, V. (2002) Novartis research move to Boston, Financial Times, 7 May, p. 28.
39. Håkanson, L. (1990) International decentralization of R&D: the organizational challenges, in: C. Bartlett, Y. Doz and G. Hedlund (Eds) Managing the Global Firm, pp. 256-278. London: Routledge.
40. Henderson, J., Dicken, P., Hess, M.et al.(2002) Global production networks and the analysis of economic development, Review of International Political Economy, 9(3), pp. 436-464.
41. Henderson, R., Orsenigo, L. and Pisano, G.P. (1999) The pharmaceutical industry and the revolution in molecular biology: interactions among scientific, institutional, and organizational change, in: D. C. Mowery and R. R. Nelson (Eds) Sources of Industrial Leadership: Studies of Seven Industries, pp. 267-311. Cambridge: Cambridge University Press.
42. Heuser, S. (2006) Novartis moving 2d unit to area; Swiss drug maker to put headquarters for vaccines, diagnostics division in Cambridge, The Boston Globe, 15 December, p. D1.
43. Hillman, M. (2006) Novartis eyes big expansion in Cambridge, Boston Business Journal, 10 November.
44. Hillman, M. (2009) Novartis AG drawing up plans for MIT parking lot, Boston Business Journal, 8 May.
45. Howells, J.R. (1996) SmithKline Beecham:global push and repositioning, in: J.-E. Nilsson, P. Dicken and J. Peck (Eds) The Internationalization Process: European Firms in Global Competition, pp. 61-73. London: Paul Chapman Publishing.
46. Howells, J.R. (1998) Innovation and technology transfer within multinational firms, in: J. Michie and J. Grieve Smith (Eds) Globalization, Growth, and Governance, pp. 50-70. Oxford: Oxford University Press.
47. Hoyler, M. (2005) Transnationale Organisationsstrukturen, vernetzte Städte: ein Ansatz zur Analyse der globalen Verflechtungen von Metropolregionen, Informationen zur Raumentwicklung, 7, pp. 431-438.
48. Hullmann, A. (2000) Generation, transfer and exploitation of new knowledge, in: A. Jungmittag, G. Reger and T. Reiss (Eds) Changing Innovation in the Pharmaceutical Industry, pp. 71-96. Berlin: Springer.
49. King, R.T.J. and Moore, S.D. (1995) Swiss stakes: Basel's drug giants are placing huge bet on U.S. biotech firms. Roche, Sandoz, Ciba Pay Up, seeking breakthrough, a strategy some deride, The Wall Street Journal Europe, 29 November, p. 1.
50. Krasner, J. (2002) Drug research giant heads to Cambridge, The Boston Globe, 7 May, p. A1.
51. Krätke, S. (2007) The metropolization of the European urban system in the era of globalization, in: P. Taylor, B. Derudder, P. Saey and F. Witlox (Eds) Cities in Globalization: Practices, Policies and Theories, pp. 157-183. London: Routledge.
52. Lazonick, W. and O'Sullivan, M. (2000) Maximizing shareholder value: a new ideology for corporate governance, Economy and Society, 29(1), pp. 13-35.
53. Lazonick, W., March, E. and Tulum, Ö. (2007) Boston's biotech boom: a 'new Massachusetts miracle'? Center of Industrial Competitiveness, University of Massachusetts Lowell, May.
54. Loder, C.M. (1999a) Key Novartis group leaving Summit site, The Star-Ledger, 30 July, p. 31.
55. Loder, C.M. (1999b) Summit looks to replace its biggest taxpayer, The Star-Ledger, 9 September, p. 29.
56. Markusen, A. (1994) Studying regions by studying firms, Professional Geographer, 46(4), pp. 477-490.
57. Maskell, P. and Malmberg, A. (1999) The competitiveness of firms and regions: 'ubiquitification' and the importance of localized learning, European Urban and Regional Studies, 6(1), pp. 9-25.
58. May, J. (2006) Mass. exodus? - New Jersey's suppremacy going south as biotech research jobs go north, The Star-Ledger, 6 August, p 1.
59. MBS (Massachusetts Biotechnology Council) and BCG (Boston Consulting Group) (2002) MassBiotech 2010: achieving global leadership in the life-sciences economy. MBC and BCG, Boston, MA.
60. McCarthy, A. (2004) Jump-starting innovation. NIBR-Science, Summer, pp. 29-32.
61. McCully, M.G. and Brunt, J. van (2005) Deal-making heads upstream, Signals Magazine, 2 April.
62. McCully, M.G. and Brunt, J. van (2006) Partnering deals: watch those milestones, Signals Magazine, 15 February.
63. Mehta and Isaly (1995) Swiss company alliances: Mehta and Isaly healthcare investments. New York, 10 October.
64. Merck (2001) Annual report 2000. Merck & Co., Inc., Whitehouse Station, NJ.
65. Merck (2002) Annual report 2001. Merck & Co., Inc., Whitehouse Station, NJ.
66. metrobasel (2006) Die Vision 2020, metrobasel report 2006. BAK Basel Economics, Basel, December.
67. metrobasel (2007) Quality of life: first-ever comparison of the Basel metropolitan region with fifteen other locations. BAK Basel Economics, Basel.
68. metrobasel (2008) Metropolitan Switzerland: Basel, Geneva and Zurich want to achieve a bigger impact by acting together. BAK Basel Economics, Basel.
69. MIT News (2002) Novartis opens drug research center in MIT's Tech Square. Media Release, Massachusetts Institute of Technology, Cambridge, MA, 6 May (http://web.mit.edu/newsoffice/nr/2002/novartis.html).
70. Morley, H.R. (2009) Merck to buy Schering: 16,000 jobs expected to be slashed, The Record, 10 March, p. B1.
71. Mowery, D.C. and Sampat, B.N. (2004) Universities in national innovation systems, in: J. Fagerberg, D. C. Mowery and R. R. Nelson (Eds) The Oxford Handbook of Innovation, pp. 209-239. Oxford: Oxford University Press.
72. NIBR (Novartis Institutes for BioMedical Research) (2007) Current alliances: Novartis Institutes for BioMedical Research (http://www.nibr.novartis.com/StrategicAlliances/current_alliances.shtml; accessed 28 January 2008).
73. Noponen, H. (1993) Scale and regulation shapes an innovative sector: jockeying for position in the world pharmaceuticals industry, in: H. Noponen, J. Graham and A. R. Markusen (Eds) Trading Industries, Trading Regions: International Trade, American Industry, and Regional Economic Development, pp. 175-211. New York: The Guilford Press.
74. Novartis (2002) Novartis steps up US research investment, opening Cambridge, Massachusetts Biomedical Research Center. Media Release, Novartis International AG, Novartis Communication, Basel, 6 May.
75. Novartis (2009a) Annual report. United States Securities and Exchange Commission Form 20-F. Novartis AG, Basel, 28 January.
76. Novartis (2009b) Novartis in der Schweiz. Novartis International AG, Public Relations Switzerland, Deutsche Ausgabe, Basel.
77. Novartis (2009c) Research & development: Novartis AG (http://www.novartis.com/research/; accessed 12 August 2009).
78. Novartis (2009d) Research and development. Novartis press kit 2009, Novartis AG, January, Basel.
79. Novartis Pharma (2000) Novartis Pharmaceuticals Corporation announces agreement to sell Summit site. Media Release, Novartis Pharmaceuticals Corporation, East Hanover, 13 July.
80. Novartis Venture Fund (2007) Novartis Venture Fund: activity report 2006. Novartis Venture Fund, Basel.
81. Novartis Venture Fund (2008) Novartis Venture Fund: activity report 2007. Novartis Venture Fund, Basel.
82. Owen-Smith, J. and Powell, W.W. (2004) Knowledge networks as channels and conduits: the effects spillovers in the Boston biotechnology community, Organization Science, 15(1), pp. 5-21.
83. Peterson, I. (2009) Smaller firms gain foothold as big drug makers shrink, The New York Times, 17 May, p. 1.
84. Peyer, C.H. (1996) Roche Geschichte eines Unternehmens 1896-1996. Basel: Editiones Roche.
85. Pike, A. (2006) 'Shareholder value' versus the regions: the closure of the Vaux Brewery in Sunderland, Journal of Economic Geography, 6(2), pp. 201-222.
86. Pisano, G. (2006) Science Business: The Promise, the Reality, and the Future of Biotech. Boston, MA: Harvard Business School Press.
87. Porter, K., Bunker Whittington, K. and Powell, W.W. (2006) The institutional embeddedness of high-tech regions: relational foundations of the Boston biotechnology community, in: S. Breschi and F. Malerba (Eds) Clusters, Networks, and Innovation, pp. 261-296. Oxford: Oxford University Press.
88. Powell, W. (1996) Inter-organizational collaboration in the biotechnology industry, Journal of Institutional and Theoretical Economies, 152(1), pp. 197-215.
89. Powell, W.W., Koput, K.W., Bowie, J.I. and Smith-Doerrs, L. (2002) The spatial clustering of science and capital: accounting for biotech firm-venture capital relationships, Regional Studies, 36(3), pp. 291-305.
90. Prevezer, M. (1998) Clustering in biotechnology in the USA, in: P. G. M. Swann, M. Prevezer and D. Stout (Eds) The Dynamics of Industrial Clustering: International Comparisons in Computing and Biotechnology, pp. 124-193. Oxford: Oxford University Press.
91. Roche (2000a) Neues Biotech-Start-Up-Unternehmen: Eine Gründung von Roche. BASILEA Pharmaceutica: eine neue Firma auf dem Gebiet der Infektionskrankheiten und der Dermatologie. Media release, F. Hoffmann-La Roche, Basel, 17 October (http://www.roche.com/roche/news/mrel00/d001017a.htm).
92. Roche (2000b) Roche setzt neuen Schwerpunkt in der Genomforschung. Media release, F. Hoffmann-La Roche, Basel, 5 June (http://www.roche.com/roche/news/mrel00/d000605a.htm).
93. Roche (2006) Roche baut Kapazitäten für galenische Produktion von Injektions-und Infusionspräparaten weiter aus. Media release, F. Hoffmann-La Roche, Basel, 15 November (http://www.roche.ch/med_151106-d.pdf).
94. Roche (2007) Roche: Grundsteinlegung für 190-Millionen-Franken-Bau in Kaiseraugst. Konzentration und Ausbau der Kapazitäten in der Sterilproduktion. Media release, F. Hoffmann-La Roche, Basel, 22 May (http://www.roche.ch/med_220507-d.pdf).
95. Roche (2009a) Roche finance report 2008. F. Hoffmann-La Roche AG, Basel.
96. Roche (2009b) Roche half-year report 2009: leading in biotechnology, improving patient care. F. Hoffmann-La Roche AG, Basel.
97. Roche (2009c) Foundation-laying ceremony for new R&D building at Roche Basel. Media release, F. Hoffmann-La Roche, Basel, 23 January (http://www.roche.com/med-cor-2009-01-23-e.pdf).
98. Roche (2009d) Roche weiht 200-Millionen-Franken-Bau in Kaiseraugst ein Kapazitäten in der Sterilproduktion ausgebaut. Media release, F. Hoffmann-La Roche, Basel, 26 June (http://www.roche.ch/med-cor-2009-06-26-d.pdf).
99. Ross, C. (2009) Novartis will expand in Cambridge: drug maker signs lease deal, plans to build a new facility, The Boston Globe, p. B1.
100. Roth, U. (2008) Region Basel: Pharma-Metropole am Tor der Schweiz, Die Volkswirtschaft, 11, pp. 47-51.
101. Rozenblat, C. and Pumain, D. (2007) Firm linkages, innovation and the evolution of urban systems, in: P. Taylor, B. Derudder, P. Saey and F. Witlox (Eds) Cities in Globalization: Practices, Policies and Theories, pp. 130-156. London: Routledge.
102. Ruigrok, W. and Tulder, R. van (1995) The Logic of International Restructuring. London: Routledge.
103. Sable, M. (2007) The impact of the biotechnology industry on local economic development in the Boston and San Diego metropolitan areas, Technological Forecasting and Social change, 74(1), pp. 36-60.
104. Sassen, S. (1994) Wirtschaft und Kultur in der globalen Stadt, in: B. Meurer (Ed.) Die Zukunft des Raums, pp. 71-89. Frankfurt/Main: Campus Verlag.
105. Schaper, E. von (2008) Novartis plans job cuts, acquisitions, The Star-Ledger, 22 October, p. 32.
106. Schering-Plough (2000) Schering-Plough announces agreement to purchase Summit, N.J., research and office facility from Novartis. Media release, Schering-Plough Corporation, Madison, NJ, 13 July.
107. Schoder, T. (2008) Der metrobasel regionen monitor: metrobasel and BAK Basel economics (http://www.metrobasel.org/downloads/projekte/plattform/p0005d94_info_2_2008_schoder.pdf?navanchor=1010006; accessed 2 June 2008).
108. Schreuder, Y. (1998) The German-American pharmaceutical business establishment in the New York metropolitan region, Environment and Planning A, 30(10), pp. 1743-1756.
109. Scott, A.J. (1988) New Industrial Spaces: Flexible Production Organization and Regional Development in North America and Western Europe. London: Pion.
110. Scott, A.J. (2000) Regions and the World Economy: The Coming Shape of Global Production, Competition, and Political Order. Oxford: Oxford University Press.
111. Serfati, C. (2008) Financial dimensions of transnational corporation, value chain and technological innovation, Journal of Innovation Economics, 2, pp. 35-61.
112. Silverman, E. (1999a) Novartis Pharmaceuticals to sell 88-acre site in Summit, N.J, The Star-Ledger, 8 September, p. 13.
113. Silverman, E. (1999b) Novartis slashes security as drug maker retrenches, The Star-Ledger, 3 September, p. 41.
114. Silverman, E. (2002a) Novartis plans to shift jobs out of state, The Star-Ledger, 7 May, p. 22.
115. Silverman, E. (2002b) Transition man: Paulo Costa is building the foundation for a new Novartis, The Star-Ledger, 5 June, p. 29.
116. Silverman, E. and Fitzgerald, B. (2004) Merged drug maker will keep U.S. base, jobs in Bridgewater, The Star-Ledger, 25 September, p. 1.
117. Smith, A., Rainnie, A., Dunford, M.et al.(2002) Networks of value, commodities and regions: reworking divisions of labour in macro-regional economies, Progress in Human Geography, 26(1), pp. 41-63.
118. Soltanifar, N. (1996) Roche research: an ever expanding frontier. Hoffmann-La Roche, Nutley, NJ.
119. Storper, M. (1997) The Regional World: Territorial Development in a Global Economy. New York: The Guilford Press.
120. Storper, M. and Walker, R. (1989) The Capitalist Imperative. NewYork: Basil Blackwell.
121. Taylor, P.J. and Walker, D.R. (2001) World cities: a first multivariate analysis of their service complexes, Urban Studies, 38(1), pp. 23-47.
122. Veltz, P. (1996) Mondialisation, Ville et Territoires: L'économie d'archipel. Paris: Presses Universitaires de France.
123. Whalen, J. (2005) Novartis's big experiment: former professor reinvents process for making drug discoveries, The Wall Street Journal, 29 November, pp. 1-2.
124. Zeller, C. (2001) Globalisierungsstrategien: Der Weg von Novartis. Berlin: Springer-Verlag.
125. Zeller, C. (2002) Project teams as means for restructuring research and development in the pharmaceutical industry, Regional Studies, 36(3), pp. 283-297.
126. Zeller, C. (2003) Restructuring knowledge acquisition and production in the pharmaceutical and biotech industries, in: V. Lo and E. Schamp (Eds) Knowledge: The Spatial Dimension, pp. 131-166. Münster: Lit-Verlag.
127. Zeller, C. (2004) North Atlantic innovative relations of Swiss pharmaceuticals and the importance of regional biotech arenas, Economic Geography, 80(1), pp. 83-111.
128. Zeller, C. (2008) From the gene to the globe: extracting rents based on intellectual property monopolies, Review of International Political Economy, 15(1), pp. 86-115.
129. Zeller, C. (2010a) Ungleiche expansion der pharmaindustrie: globale warenketten and aufstieg Indiens and Chinas, in: K. Fischer, C. Reiner and C. Staritz (Ed.) Globale Güterketten: Weltweite Arbeitsteilung and Ungleiche Entwicklung, pp. 221-245. Wien: Promedia.
130. Zeller, C. (2010b) Financing biotechnology in the US in a finance-dominated accumulation regime, Geoforum (forthcoming).